Physician profile
Bruce Dorr
NPI 1669430716
$3,379.40
in general payments reported to CMS, 2019-2025
35 companies · $407 in 2025
The $407 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $414 · 2021: $475 · 2022: $583 · 2023: $462 · 2024: $415 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,267 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,266.58 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $985.34 | 2019-2025 | Liletta, Lo Loestrin Fe, Orilissa |
| Hologic Sales and Service, LLC | $292.64 | 2019-2025 | Novasure, Myosure Tissue Removal Device, Acessa Provu System |
| Mayne Pharma Commercial LLC | $211.24 | 2021-2025 | |
| Eisai INC. | $177.21 | 2020-2021 | |
| Coloplast Corp | $161.75 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $158.77 | 2020-2025 | |
| Therapeuticsmd, INC. | $146.97 | 2019-2022 | |
| Medtronic, INC. | $137.18 | 2024 | Abre |
| Merck Sharp & Dohme LLC | $130.76 | 2020-2025 | Gardasil 9 |
| Astellas Pharma US INC | $94.41 | 2022-2025 | Veozah |
| Intuitive Surgical, INC. | $88.25 | 2022 | |
| Ascend Therapeutics US, LLC | $82.96 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $68.55 | 2023-2024 | Myfembree |
| Avion Pharmaceuticals | $48.02 | 2021 | |
| Allergan, INC. | $47.97 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caldera Medical, INC | $47.52 | 2022 | |
| Coopersurgical, INC. | $46.65 | 2021-2024 | Paragard T 380a, Paragard T 380a |
| Revance Therapeutics, INC. | $43.05 | 2025 | Daxxify |
| Organon LLC | $40.45 | 2022-2024 | |
| Celgene Corporation | $38.68 | 2023 | Reblozyl |
| Idorsia Pharmaceuticals US INC | $36.83 | 2023 | Quviviq |
| Exeltis, USA INC. | $29.66 | 2024-2025 | Slynd |
| Galderma Laboratories, L.P. | $28.99 | 2022-2025 | Dysport |
| Myovant Sciences INC. | $26.88 | 2022 | |
| Meditrina | $26.67 | 2021 | |
| Dysis Medical, INC. | $25.02 | 2021 | |
| Vertical Pharmaceuticals, LLC | $24.29 | 2019 | |
| Ibsa Pharma INC. | $21.85 | 2024 | Tirosint, Licart |
| Evofem Biosciences, INC. | $18.41 | 2021 | |
| Lilly USA, LLC | $17.63 | 2025 | Zepbound |
| Pfizer INC. | $17.44 | 2023 | |
| Shield Therapeutics INC | $16.85 | 2023 | Accrufer |
| Integra Lifesciences Corporation | $14.51 | 2025 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Lupin INC. | $14.44 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Dorr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.